China-only trials rarely meet FDA expectations on population diversity, GCP and inspection access. Here is why MRCT-aligned evidence is now essential for U.S. market entry.
As global regulatory expectations continue to rise, the U.S. Food and Drug Administration (FDA) has reinforced its position on the acceptance of foreign clinical data — particularly studies conducted solely in China. Under the FDA guidance Acceptance of Foreign Clinical Studies Not Conducted Under an IND, foreign data must meet strict criteria related to data integrity, Good Clinical Practice (GCP) compliance, and applicability to the U.S. population.
China-only clinical trials often face challenges in meeting these expectations. FDA has repeatedly emphasized the importance of population diversity, multi-regional representation, and site inspection accessibility. Trials conducted exclusively in one country may not reflect the genetic, demographic, or clinical characteristics of U.S. patients, limiting the FDA’s ability to rely on such data for safety and effectiveness evaluations.
In addition, FDA’s increasing scrutiny of data reliability — especially when inspection access is limited — has led to more requests for supplemental U.S. or multi-regional clinical trial (MRCT) data. ICH E5 and ICH E17 guidelines further reinforce the need for cross-regional applicability and harmonized MRCT design.
For MedTech and pharmaceutical companies planning U.S. submissions, the implication is clear: China-only data is rarely sufficient, and early planning for MRCT-aligned evidence generation is now essential.
Sources:
FDA — Acceptance of Foreign Clinical Studies Not Conducted Under an IND
ICH E5 (Ethnic Factors)
ICH E17 (Multi-Regional Clinical Trials)
